Earn Perry
Founder bei Musli Thyropeutics Ltd.
Profil
Earn Perry is a managing director and founder of Maruho Israel Innovation Fund, which was founded in 2018.
He is also the founder of ICD Pharma Ltd., Musli Thyropeutics Ltd., and Upstream Bio, Inc. Currently, he holds the position of Director at MyBiotics Pharma Ltd.
Mr. Perry has an MBA from The Trustees of Columbia University in The City of New York and has completed undergraduate and graduate degrees from Tel-Aviv University.
Aktive Positionen von Earn Perry
| Unternehmen | Position | Beginn |
|---|---|---|
| Musli Thyropeutics Ltd. | Founder | - |
MyBiotics Pharma Ltd.
 MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Director/Board Member | - |
Ehemalige bekannte Positionen von Earn Perry
| Unternehmen | Position | Ende |
|---|---|---|
Maruho Israel Innovation Fund
 Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | Founder | - |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Founder | - |
| ICD Pharma Ltd. | Founder | - |
Ausbildung von Earn Perry
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Tel-Aviv University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Health Technology |
| Musli Thyropeutics Ltd. | |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | Finance |
| ICD Pharma Ltd. | |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
